Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -167.64% is 76% below its 5-year average of -95.34%, near the low end of its 5-year range (-194.99%–-37.09%).
8.87% above its 12-month average of -183.95%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -38.24%.
RETURN ON ASSETS (ROA)
-167.64%
RETURN ON ASSETS (ROA) AVG TTM
-183.95%
RETURN ON ASSETS (ROA) AVG 3Y
-119.46%
RETURN ON ASSETS (ROA) AVG 5Y
-95.34%
RETURN ON ASSETS (ROA) AVG 10Y
-102.65%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.87%
CURRENT VS 3Y AVG
-40.33%
CURRENT VS 5Y AVG
-75.84%
CURRENT VS 10Y AVG
-63.32%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 560 covered companies
CURRENT VS SECTOR MEDIAN
-497.75%
vs the sector median at left
Insight Molecular Diagnostics Inc.
Market Cap
$120.28M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$120.68M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$118.38M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$122.26M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$118.02M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$122.89M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$116.95M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$115.06M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$114.42M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.28M | -167.64% | -183.95% | -119.46% | -95.34% |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.68M | -96.49% | -109.25% | -126.41% | -190.40% |
| Genelux Corporation (GNLX)vs › | $118.38M | -128.96% | -127.49% | -112.64% | -129.28% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | -1.70% | -35.34% | -51.03% | -36.99% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -72.42% | -66.03% | -45.57% | -48.77% |
| Cibus, Inc. (CBUS)vs › | $122.89M | -31.33% | -56.73% | -59.49% | -64.55% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.95M | -53.26% | -24.98% | -43.10% | -143.56% |
| Coya Therapeutics, Inc. (COYA)vs › | $115.06M | -0.05% | -38.03% | -60.31% | -59.32% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.42M | -134.18% | -145.83% | -164.39% | -180.40% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.14M | -31.75% | -34.00% | -32.33% | -29.29% |
ROA
-167.6%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -194.99% |
| 2024-12-31 | -172.92% |
| 2023-12-31 | -37.09% |
| 2022-12-31 | -72.84% |
| 2021-12-31 | -40.17% |
| 2020-12-31 | -54.01% |
| 2019-12-31 | -56.02% |
| 2018-12-31 | -165.52% |
| 2017-12-31 | -189.65% |
| 2016-12-31 | -77.30% |
| 2015-12-31 | -68.61% |
| 2014-12-31 | -78.45% |
| 2013-12-31 | -42.17% |
